Abstract
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma
Journal of clinical oncology, Vol.36(15_suppl), pp.4510-4510
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.4510
Abstract
Abstract only
Details
- Title: Subtitle
- A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma
- Creators
- Ulka N. Vaishampayan - The Barbara Ann Karmanos Cancer InstituteDavid F. McDermott - Beth Israel Deaconess Medical CenterMarc Ryan Matrana - Ochsner Medical CenterSun Young Rha - Yonsei UniversityAmado J. Zurita - The University of Texas MD Anderson Cancer CenterThai Huu Ho - Mayo Clinic in ArizonaBhumsuk Keam - Seoul National University HospitalJae-Lyun Lee - University of UlsanRichard Wayne Joseph - Mayo Clinic in FloridaSarah Ali - Michigan State UniversityWalter Michael Stadler - University of ChicagoNaomi B. Haas - Penn Center for AIDS ResearchSrinath Sundararajan - University of ArizonaSe Hoon Park - Samsung Medical CenterRex B. Mowat - Toledo Clinic Cancer CenterJoel Picus - Washington University in St. LouisArkadiusz Z. Dudek - HealthPartnersYousef Zakharia - University of IowaLu Gan - Epix PharmaceuticalsMichael B. Atkins - Georgetown University
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.4510-4510
- DOI
- 10.1200/JCO.2018.36.15_suppl.4510
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548382002771
Metrics
2 Record Views